psilocin IV-infused (TRP-8803) / Tryp Therap - LARVOL DELTA

A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants (ANZCTR) - P1 | N=9 | Completed | Sponsor: Tryp Therapeutics, Inc. | Not yet recruiting ➔ Completed

Trial completion

Testing the Safety and Effects of the Psychedelic Psilocin on Wellbeing and Anxiety in People with Ongoing Physical and Mental Health Conditions (ANZCTR) - P1 | N=66 | Not yet recruiting | Sponsor: Tryptamine Therapeutics

HEOR • New P1 trial • Pan tumor • Anorexia • CNS Disorders • Depression • Fatigue • Fibromyalgia • Gastrointestinal Disorder • General Anxiety Disorder • Infectious Disease • Major Depressive Disorder • Mood Disorders • Musculoskeletal Pain • Novel Coronavirus Disease • Obsessive-Compulsive Disorder • Pain • Post-traumatic Stress Disorder • Psychiatry • Psychosomatic Disorders • Rheumatology

Evaluation of the safety of the intravenously (IV) administered psychedelic, psilocin in healthy adults. (ANZCTR) - P1 | N=4 | Not yet recruiting | Sponsor: Tryptamine Theraputics

New P1 trial • Binge Eating Disorder • CNS Disorders

Safety, Feasibility and Initial Efficacy of IV infused Psilocin (TRP-8803) Administration in combination with Psychotherapy Among Adults with Binge Eating Disorder (ANZCTR) - P1 | N=12 | Not yet recruiting | Sponsor: Tryptamine Theraputics

New P1 trial • Binge Eating Disorder • CNS Disorders